Accurate1, non-invasive, continuous, wireless BP monitoring for neonatal and pediatric patients.
Learn More
PyrAmes platforms will provide options to continuously monitor blood pressure cNIBP for patients of all ages.
could benefit from BP monitoring but would not receive an arterial line because it is invasive and costly.2
50% of adults are affected by high blood pressure in the US, increasing their mortality rates.3
Raised blood pressure (BP) is responsible for 7.6 million deaths worldwide annually.4
cNIBP has the potential for early detection of conditions within preterm infants and adults.
PyrAmes, a digital health company advancing noninvasive patient monitoring, announced today that it won the SCCM Pitch Award at the Pitch-a-Palooza: Showcasing Innovations in Critical Care event at the 2026 Critical Care Congress hosted by the Society of Critical Care Medicine in Chicago, Illinois. The award was presented as part of the conference’s innovation programming, recognizing breakthrough technologies with the potential to transform critical care. PyrAmes received a $10,000 prize for its presentation, “Creating a New Standard of Care for Blood Pressure Measurement,” delivered by Xina Quan, PhD, Co-Founder and CEO of PyrAmes.
(more…)
PyrAmes published Accuracy and Safety of a Continuous Noninvasive Blood Pressure Monitor in Neonates in Neonatology, a leading publication for fetal and neonatal research. The paper describes PyrAmes’ successful pivotal clinical study for Boppli®, its groundbreaking blood pressure monitoring solution for infants under critical care. The study, at five hospitals in the U.S. and Canada, compared Boppli’s blood pressure readings to those from arterial lines. The study found Boppli to be a promising alternative to cumbersome cuffs (providing only spot measurements) or invasive arterial lines for continuous noninvasive BP monitoring in infants, offering good accuracy and usability. Boppli does not require calibration. Study results were submitted to the FDA, resulting in 510(K) clearance.
The American Heart Association Center for Health Technology & Innovation selected PyrAmes as the best business pitch by a panel of expert judges at its annual Health Tech Competition during Scientific Sessions 2023. PyrAmes was one of five finalists in AHA’s competition, which aims to drive innovation and foster advancements with the potential to transform the landscape of heart and brain health.
2023 American Heart Association Health Tech Competition
2023 FDA 510(k) Clearance
2023 NIH RADx Tech Maternal Health Challenge
2020 FDA Breakthrough Device Designation
Founding Member of CDC National Hypertension Control Roundtable